Is Napavir Sodium/Salanka currently on the market?

Lenapavir sodium/Sunlenca (Sunlenca) is an innovativeHIV-1 antiviral drug, specially developed for patients with multidrug-resistant HIV infection. The drug is unique in its mechanism of action and long-acting properties, making its global launch a major advance in HIV treatment and prevention. Lenapavir sodium can effectively inhibit the spread of HIV-1 in the body by inhibiting the assembly and function of viral capsid proteins and interfering with multiple key steps of viral replication, including viral nuclear uptake, assembly and release. This mechanism is different from traditional reverse transcriptase inhibitors or protease inhibitors, giving it significant efficacy in multidrug-resistant patients.

In terms of global marketing, lenapavir sodium was first approved in the EU in August 2022, under the trade name Sunlenca, for the treatment of adult HIV-1 infected patients who have received multiple antiretroviral drugs but have not effectively controlled the virus; subsequently, in December of the same year, the United States also approved the marketing of Sunlenca, further expanding its international accessibility. China officially approved the marketing of lenapavir sodium in December 2024, with the trade name Salanka, making it the first domestic long-acting antiviral drug for patients with multidrug-resistant HIV infection. It is worth noting that lenapavir sodium is available in tablet and injection forms globally to meet the treatment needs of different patients while improving compliance and quality of life.

In clinical use, the injection form of lenapavir sodium only needs to be injected once every six months, which significantly reduces the burden of daily medication and is especially suitable for patients who have failed long-term multi-drug therapy. Tablet dosage forms provide flexible dosing methods and facilitate individualized treatment. Patients need to follow a strict treatment plan during use and inject or take medicines on time to prevent the occurrence of viral resistance. During treatment management, doctors will formulate specific doses and plans based on the patient's weight, viral load, and previous treatment history to ensure that the drug maintains an effective concentration in the body and achieves sustained viral suppression.

Reference materials:https://www.drugs.com/sunlenca.html